|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?显示文摘In recent years,there has been a critical change in treatment paradigms in inflammatory bowel diseases(IBD)triggered by the arrival of new effective treatments aiming to prevent disease progression,bowel damage and disability.The insufficiency of symptomatic disease control and the well-known discordance between symptoms and objective measures of disease activity lead to the need of reviewing conventional treatment algorithms and developing new concepts of optimal therapeutic strategy.The treat-to-target strategies,defined by the selecting therapeutic targets in inflammatory bowel disease consensus recommendation,move away from only symptomatic disease control and support targeting composite therapeutic endpoints(clinical and endoscopical remission)and timely assessment.Emerging data suggest that early therapy using a treat-to-target approach and an algorithmic therapy escalation using regular disease monitoring by clinical and biochemical markers(fecal calprotectin and C-reactive protein)leads to improved outcomes.This review aims to present the emerging strategies and supporting evidence in the current therapeutic paradigm of IBD including the concepts of“early intervention”,“treat-to-target”and“tight control”strategies.We also discuss the real-word experience and applicability of these new strategies and give an overview on the future perspectives and areas in need of further research and potential improvement regarding treatment targets and(“tight”)disease monitoring strategies. | Lorant Gonczi Talat Bessissow Peter Laszlo Lakatos | 2019 | World Journal of Gastroenterology2019，25，41： | 4 |
| 2 | Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases显示文摘The past decade has brought substantial advances in the management of inflammatory bowel diseases(IBD). The introduction of tumor necrosis factor(TNF) antagonists, evidence for the value of combination therapy, the recog-nition of targeting lymphocyte trafficking and activation as a viable treatment, and the need for early treatment of high-risk patients are all fundamental concepts for current modern IBD treatment algorithms. In this article, authors review the existing data on approved biologicals and small molecules as well as provide insight on the current positioning of approved therapies. Patient stratification for the selection of specific therapies, therapeutic targets and patient monitoring will be discussed as well. The thera-peutic armamentarium for IBD is expanding as novel and more targeted therapies become available. In the absence of comparative trials, positioning these agents is becoming difficult. Emerging concepts for the future will include an emphasis on the development of algorithms which will facilitate a greater understanding of the positioning of novel biological drugs and small molecules in order to best tailor therapy to the patient. In the interim, anti-TNF therapy remains an important component of IBD therapy with the most real-life evidence and should be considered as first-line therapy in patients with complicated Crohn's disease and in acute-severe ulcerative colitis. The safety and efficacy of these ‘older' anti-TNF therapies can be optimized by adhering to therapeutic algorithms which combine clinical and objective markers of disease severityand response to therapy. | Jason Reinglas Lorant Gonczi Zsuzsanna Kurt Talat Bessissow Peter L Lakatos | 2018 | World Journal of Gastroenterology2018，24，32： | 3 |
| 3 | Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?显示文摘Inflammatory bowel disease(IBD) is a lifelong, progres-sive disease that has disabling impacts on patient's lives. Given the complex nature of the diagnosis of IBD and its management there is consequently a large economic burden seen across all health care systems. Quality in-dicators(QI) have been created to assess the different fa?ades of disease management including structure, process and outcome components. Their development serves to provide a means to target and measure quality of care(Qo C). Multiple different QI sets have been published in IBD, but all serve the same purpose of trying to achieve a standard of care that can be attained on a national and international level, since there is still a major variation in clinical practice. There have been many recent innovative developments that aim to improve Qo C in IBD including telemedicine, home biomarker assessment and rapid access clinics. These are some of the novel advancements that have been shown to have great potential at improving Qo C, while offloading some of the burden that IBD can have vis-a-vis emergency room visits and hospital admissions. The aim of the current review is to summarize and discuss available QI sets and recent developments in IBD care including telemedicine, and to give insight into how the utilization of these tools could benefit the Qo C of IBD patients. Additionally, a treating-to-target structure as well as evidence surrounding aggressive management directed at tighter disease control will be presented. | Matthew Strohl Lorant Gonczi Zsuzsanna Kurt Talat Bessissow Peter L Lakatos | 2018 | World Journal of Gastroenterology2018，24，22： | 2 |
| 4 | Functional genomic analysis of cell divisive in C elegans using RNAi of gene chromosome显示文摘 | GONCZY P ECHEVERRIC C OEGOMA K | 2000 | Nature2000，408，： | 1 |
| 5 | Does resident involvement effect surgical times and complication rates during laparoscopic appendectomy for uncomplicated appendicitis?An analysis of 16,849 cases from the ACS-NSQIP显示文摘 | Advani V Ahad S Gonczy C | 2012 | Am J Surg2012，203，3： | 1 |
| 6 | Coupling of cortical dynein and Galpha proteins mediates spindle positioning in Caenorhabditis elegans显示文摘 | Nguyen-Ngoc T Afshar K Gonczy P | 2007 | Nat Cell Biol2007，10，10： | 1 |
| 7 | Competency-based assessment in the professions in Australia 显示文摘 | Gonczi | 1994 | Assessment in Education1994，1，1： | 1 |
| 8 | Future directions for vocational education in Australian Secondary Schools显示文摘 | Gonczi A | 2001 | Aust New Zeal J Vocat Educ Res2001，5，1： | 1 |
| 9 | Effects of chronic manganese exposure on cognitive and motor functioning in non-human primates 显示文摘 | Sclmeider JS Decamp E Koser A J Fritz S Gonczi H Syversen T | | Brain Res0，1118，1： | 1 |
| 10 | In vivo kinetics of magnetically targeted low-dose doxorubicin显示文摘 | Senyei A E Reich S D Gonczy C | 1981 | J Pharm Sci1981，70，4： | 1 |
| 11 | Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischaemic preconditioning显示文摘 | Papp R Gonczi M Kovács M | 2007 | Cardiovascular2007，74，3： | 1 |
| 12 | Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischaemia precon- ditioning 显示文摘 | Papp R Gonczi M Kovacs M | 2007 | Cardiovasc Res2007，74，： | 1 |
| 13 | Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischemic preconditioning显示文摘 | Papp R Gonczi M Kovacs M | 2007 | Cardiovasc Res2007，74，3： | 1 |
| 14 | In vitro kinetics of magnetically targeted low dose doxorubicin显示文摘 | Senyei AE Reich SD Gonczy C | 1981 | J Pharm Sci1981，70，4： | 1 |
| 15 | ProTides of N- ( 3-( 5-( 20-deoxyuridine ) ) prop-2-ynyl ) octanamide as potential anti-tubercular and anti,viral agents 显示文摘 | MCGUIGAN C DERUDAS M GONCZY B | 2014 | Bioorg Med Chem2014，22，9： | 1 |
| 16 | In vivo kinetics of magnetically targeted low-dose Doxorubicin显示文摘 | Senyei AE Reich SD Gonczy C | 1981 | J Pharm Sci1981，70，4： | 1 |
| 17 | Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center:Access, resource utilization and outcomes显示文摘BACKGROUND Emergency situations in inflammatory bowel diseases(IBD)put significant burden on both the patient and the healthcare system.AIM To prospectively measure Quality-of-Care indicators and resource utilization after the implementation of the new rapid access clinic service(RAC)at a tertiary IBD center.METHODS Patient access,resource utilization and outcome parameters were collected from consecutive patients contacting the RAC between July 2017 and March 2019 in this observational study.For comparing resource utilization and healthcare costs,emergency department(ED)visits of IBD patients with no access to RAC services were evaluated between January 2018 and January 2019.Time to appointment,diagnostic methods,change in medical therapy,unplanned ED visits,hospitalizations and surgical admissions were calculated and compared.RESULTS 488 patients(Crohn’s disease:68.4%/ulcerative colitis:31.6%)contacted the RAC with a valid medical reason.Median time to visit with an IBD specialist following the index contact was 2 d.Patients had objective clinical and laboratory assessment(C-reactive protein and fecal calprotectin in 91%and 73%).Fast-track colonoscopy/sigmoidoscopy was performed in 24.6%of the patients,while computed tomography/magnetic resonance imaging in only 8.1%.Medical therapy was changed in 54.4%.ED visits within 30 d following the RAC visit occurred in 8.8%(unplanned ED visit rate:5.9%).Diagnostic procedures and resource utilization at the ED(n=135 patients)were substantially different compared to RAC users:Abdominal computed tomography was more frequent(65.7%,P<0.001),coupled with multiple specialist consults,more frequent hospital admission(P<0.001),higher steroid initiation(P<0.001).Average medical cost estimates of diagnostic procedures and services per patient was$403 CAD vs$1885 CAD comparing all RAC and ED visits.CONCLUSION Implementation of a RAC improved patient care by facilitating easier access to IBD specific medical care,optimized resource utilization and helped avoiding ED visits and subsequent hospitalizations. | Sofia Nene Lorant Gonczi Zsuzsanna Kurti Isabelle Morin Kelly Chavez Christine Verdon Jason Reinglas Rita Kohen Talat Bessissow Waqqas Afif Gary Wild Ernest Seidman Alain Bitton Peter Laszlo Lakatos | 2020 | World Journal of Gastroenterology2020，26，7： | 1 |
| 18 | Functional genomic analysis of cell division in C elegans using RNAi of genes on chromosome Ⅲ 显示文摘 | Gonczy P Echeverri C | 2000 | Nature2000，408，6810： | 1 |
| 19 | Detection of feline leukemia virus RNA in saliva from naturally infected cats and correlation of PCR results with those of current diagnostic methods显示文摘 | Gomes-Keller M A GOnczi E Tandon R | 2006 | J Clin Microbiol2006，44，3： | 1 |
| 20 | Fecal shedding of infectious feline leukemia virus and its nucleic aeids: a transmission potential显示文摘 | Gomes-Keller M A Gonczi E Grenacher B | 2009 | Vet Microbiol2009，134，34： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员